\nClinical research teams today face increasing pressures: the need to reduce complexity in workflows, intensifying oversight demands especially for multi-market and decentralized trials, and the common challenges of data silos, system incompatibility and poor data governance.\n<\/p>\n
\nFor Contract Research Organizations (CROs) navigating these hurdles, rethinking how clinical operations are run can help transform their clinical operations. I spoke with Peter Legget, Project Management Office Manager at Novotech, to hear how their teams made that shift and what that journey means for the future of modern CROs.\n<\/p>\n
\nAs Novotech expanded capabilities to support next-generation therapies, a common industry challenge emerged: fragmentation. Critical functions such as CTMS, TMF, and Safety were running on disconnected platforms, while SSU and Feasibility were run on on-premise systems. Study training tracking was handled manually and not directly linked to key documents in TMF, leaving compliance visibility gaps across studies.\n<\/p>\n
\nWithout system-enforced dependencies between submissions and site activation, it was a challenge to ensure consistency in sequencing activities. Client access and oversight were equally limited, with study data shared through offline reports and static snapshots rather than live views, making timely oversight difficult for sponsors.\n<\/p>\n
\nThe cumulative effect was a lack of visibility, connection, and standardization across start-up processes, study training, and quality control, creating a dependency on manual tracking that constrained Novotech’s ability to scale.\n<\/p>\n
\n\u201cIn critical areas like clinical data management and pharmacovigilance, the lack of system integration limited our ability to take a holistic risk-based approach to trial oversight,\u201d says Peter.\n<\/p>\n
\nNovotech\u2019s evaluation was not simply about replacing one system with another. The goal was to find a platform capable of supporting end-to-end clinical trial management to eliminate manual dependencies and visibility gaps that held the organization back.\n<\/p>\n
\nAdopting ³Ô¹Ï±¬ÁÏ\u2019s Clinical Suite addresses these challenges at the root. As Peter describes, it has \u201cfundamentally transformed (their) operations, delivering greater visibility, automation, and control across the clinical lifecycle.\u201d By consolidating previously disconnected and offline functions like CTMS, Payments, and SSU onto a single unified platform, Novotech replaced fragmented manual workflows with connected, automated processes across the full trial lifecycle.\n<\/p>\n
\nNovotech leverages ³Ô¹Ï±¬ÁÏ Connections to automate data exchange between internal systems such as EDC and CTMS, EDC and Safety as well as eTMF and Study Training. This eliminates manual reconciliation and ensures real-time visibility. Across functions, the impact directly addresses the fragmentation that once defined Novotech’s operations:\n<\/p>\n
\nSSU:<\/strong> System-enforced prerequisites now govern site activation based on submission status, with linked document management providing clear visibility into planned versus actual submissions and their associated approvals.\n<\/p>\n \nStudy Training<\/strong> has moved from entirely manual processes to auto training requirement (Training Requirement) creation per auto-training matrix, with clinical documents now directly connected to their corresponding training records.\n<\/p>\n \nTMF:<\/strong> Within the TMF, Novotech now has standardized filing and system-enforced documentation levels at each study milestone.\n<\/p>\n \nCTMS:<\/strong> Key documents including selection, activation, and monitoring event letters are now auto-generated and linked directly to the TMF, while PD reviews happen on-platform for real-time client collaboration.\n<\/p>\n \nSafety:<\/strong> What was previously a standalone silo, now has gateway connections established for safety report submission, bringing one of the most compliance-critical functions into a unified ecosystem.\n<\/p>\n \nBeyond individual functions, the broader integration between ³Ô¹Ï±¬ÁÏ CDMS and RAVE, with CTMS creates a connected data backbone that extends well beyond operational efficiency. For a CRO scaling across APAC, North America, and Europe, this level of connectivity directly addresses the fragmentation that once constrained growth.\n<\/p>\n \nNovotech’s journey with ³Ô¹Ï±¬ÁÏ offers a clear blueprint for CROs navigating the same pressures. The central lesson is not simply about technology adoption, but about what becomes possible when fragmented systems are replaced with a unified foundation. Clean, connected data is the prerequisite for real-time visibility, meaningful sponsor collaboration, and inspection readiness.\n<\/p>\n \nThis is becoming increasingly crucial for every modern CRO, enabling sponsors to rely on live study data and on-platform workflows as a robust foundation for more effective operations. Additionally, the importance of building a scalable framework from the outset cannot be overstated. System-enforced dependencies and automated reporting are what allow a CRO to expand and scale up without reintroducing the manual bottlenecks that are commonly characteristic of legacy systems.\n<\/p>\n \nFor Novotech, these lessons are already shaping what comes next \u2013 a clinical lifecycle where teams, sites, and sponsors collaborate seamlessly from study design to close-out, with ³Ô¹Ï±¬ÁÏ Vault as the single source of truth at every touchpoint. As Peter puts it, “we no longer move data \u2014 data moves with us.”\n<\/p>\nThe Blueprint for Modern Clinical Operations<\/h2>\n